You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Stat News reports some health tech startups are laying off or furloughing workers.
CNBC discusses factors contributing to the state of direct-to-consumer genetic testing.
Ancestry is laying off about 6 percent of its workforce due to a decline in customer demand.
CEO Margo Georgiadis said that the company has "seen a slowdown in consumer demand across the entire DNA category."
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
The layoffs occurred across 23andMe's consumer business, which is being restructured, but did not impact its therapeutics business.
The New York Times reports the Infectious Disease Research Institute in Seattle has laid off about a third of its researchers.
In a Twitter message dated Dec. 4, the company said it is suspending its US operations for the time being "due to an unexpected adverse financing situation."
The firm disclosed to the state of California that it plans to lay off 42 employees in San Diego and 16 employees in Foster City.
Several genetic test providers thought Helix would give them a national sales channel for their genomics apps, but this didn't materialize.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.